Ceptaris Therapeutics

Ceptaris Therapeutics is a privately held specialty pharmaceutical company developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early-stage (I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). If approved, Ceptaris' investigational drug would become the first topical mechlorethamine product available for treating the signs and symptoms of this rare cancer.